Overview
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
Status:
Completed
Completed
Trial end date:
2006-12-01
2006-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- BMI 27-35 kg/m2
Exclusion Criteria:
- Women of childbearing potential